Capture of CH1-Containing Bispecific Antibodies: Evaluating an Alternative to Protein A
The number of bispecific antibodies (BsAbs) in clinical testing is growing rapidly, and so is the need for efficient production and purification strategies. The main challenge of producing BsAbs is its purification process.
The common method for purifying monoclonal antibodies (MAbs) and BsAbs following harvest and clarification uses affinity capture with a commercially available protein A resin. However, this method can be challenging with BsAbs because of the multiplicity of structures.
In the article “Capture of CH1-Containing Bispecific Antibodies: Evaluating an Alternative to Protein A,” our team investigated the use of an alternative purification method for BsAbs – a commercially available CaptureSelect CH1-XL affinity resin. This article is available on the BioProcess International website.
Experts behind the article:
- Steven M. Chamow
- Angela Linderholm
- Katherine E. Harris
- Ute Schellenberger
- Brett Jorgensen
- Payal P. Pratap
Contact us to discover how our team’s comprehensive knowledge in biologics, MAbs, and bsAbs products can make a significant difference in your development journey.